Dianthus Therapeutics, Inc.
DNTH
Rank in Stocks
#4061
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Share Price
$71.45
Last synced: 2026-10-16
Market Cap
$4.00B
Change (1 day)
-4.13%
Change (1 year)
100.42%
Country
US
Trade Dianthus Therapeutics, Inc. (DNTH)
Category
Healthcare
EPS for Dianthus Therapeutics, Inc. (DNTH)
EPS as of June 2026 TTM: $-0.13
According to Dianthus Therapeutics, Inc. latest financial reports and stock price the company's current EPS (TTM) is $-0.13. At the end of 2023 the company had a EPS of $-8.45 an increase over its 2022 EPS that were of $-7.60.
EPS history for Dianthus Therapeutics, Inc. from 2016 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.13 | -94.90% |
| 2024 | $-2.55 | -69.82% |
| 2023 | $-8.45 | 11.18% |
| 2022 | $-7.60 | 98.95% |
| 2021 | $-3.82 | -86.01% |
| 2020 | $-27.30 | -17.72% |
| 2019 | $-33.18 | 20.13% |
| 2018 | $-27.62 | 72.09% |
| 2017 | $-16.05 | 275.88% |
| 2016 | $-4.27 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $17.32 | -13,423.08% |
US
|
|
| $-7.98 | 6,038.46% |
US
|
|
| $-5.29 | 3,969.23% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -21,438.46% |
NL
|
